The National Markets and Competition Commission upholds the legality of the free price policies applied by several pharmaceutical companies in Spain

In a resolution passed on 30 August 2018 the National Markets and Competition Commission brought to an end the infringement proceedings initiated against six multinational pharmaceutical companiesfor alleged practices prohibited.

October 29, 2018

In a resolution passed on 30 August 2018 (File S/DC/0608/17, EAEPC vs Pharmaceutical Companies - the “Resolution”), the National Markets and Competition Commission brought to an end the infringement proceedings initiated against six multinational pharmaceutical companies (Pfizer, Lilly, Janssen-Cilag, Novartis, Sanofi and MSD) for alleged practices prohibited by article 1 of the Spanish Competition Law and by Article 101 of the Treaty on the Functioning of the European Union. The practices in question mainly consisted of setting up an alleged dual-pricing system for their medicines, depending on whether they were dispensed in Spain or intended for intra-community trade or export.

For more information, please follow the link.